LIPOSOME DELIVERY OF ADAM-10 ACTIVATORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE

Alzheimer’s disease (AD) is an irreversible, progressive neurological brain disorder that slowly destroys the memory and thinking skills in people, and, eventually, their ability to carry out the simplest tasks. Estimates vary, but experts suggest that more than 5.5 million Americans, most of them age 65 or older, may have dementia caused by Alzheimer’s. Currently there is no known cure or preventative measure for this disease.

SwRI formulated drug-loaded, stable, blood-brain barrier (BBB) targeting liposome formulations and to develop experimental in-vitro models and computational models that can precisely evaluate the delivery of those liposome-nanoparticles based on the interaction of the BBB and liposome-nanoparticles.